‘栄研’

News Release

October 31, 2024

Company EIKEN CHEMICAL CO.,LTD.
Representative Tsugunori Notomi,
President & CEO
Code number 4549 TSE Prime

Notice of Investment in Nanotis, a Startup of Next-gen, Saliva-Based Infectious Disease Digital Testing Technology

Eiken Chemical Co., Ltd. (Headquarters: Taito-ku, Tokyo) is pleased to announce that, as part of the first strategic investment under its “EIKEN ROAD MAP 2030”, it has made an equity investment in Nanotis Corporation (Headquarters: Shibuya-ku, Tokyo; CEO, Founder: Lisa Sakashita), a startup collaborating with the University of Tokyo, developing next-generation saliva-based digital diagnostic devices for infectious diseases. The investment was made through a third-party allocation of shares in the Seed 2 round (Series B preferred stock).

1. Investment Objective

Nanotis is a startup founded in 2016 collaborating with the University of Tokyo. With the mission to "shape a world free from fear of infections," the company is engaged in the research and development of accurate, rapid, simple, and affordable digital diagnostic devices. Its patented core technology, Nucleic Acid Navigated Optically Traceable Immuno-Sensing (NANOTIS method) ※1, is the first in the world to integrate the concept of "concentration" using dielectrophoresis into detection technology, offering a revolutionary approach. Since its Seed finance in 2022, Nanotis has advanced Proof-of-Concept (PoC) studies in the laboratory and successfully demonstrated rapid detection of its first target virus, influenza. The NANOTIS method has the potential to be applied not only to infectious diseases but also to a wide range of biological particles. Its rapid results, which can be compiled in real-time, suggest potential future applications in disease surveillance and telemedicine, aligning with the growing field of digital health.

Our company is dedicated to providing products and services that safeguard health and life, guided by our management philosophy: “Protect the health of the public through health care services”. Through this capital alliance, we aim to position Nanotis as a strong partner for advancing the research, development, and implementation of the NANOTIS method, with the goal of manufacturing and distributing next-generation diagnostic kits accessible to anyone, anytime, anywhere.

2. Method of Share Acquisition

Eiken Chemical acquired all Series B preferred shares issued by Nanotis on October 29, 2024.

3. About Nanotis

Name: Nanotis Corporation

CEO, Founder : Lisa Sakashita

Headquarters:5-50-13 Yoyogi Shibuya-ku Tokyo 151-0053

Joint Research Laboratory: Building 4, Faculty of Engineering, 7-3-1 Hongo Bunkyo-ku Tokyo 113-8656

Laboratory: Yushima and Surugadai Campus, Institute of Science Tokyo, 1-5-45 Yushima Bunkyo-ku Tokyo 113-8510 (previously, Tokyo Medical and Dental University Innovation Park)

Established: June 6, 2016

Capital: 100 million yen

Business Activities: Research and development of rapid infectious disease testing devices

Website: http://nanotis.net/

Concept video: https://vimeo.com/880363397

■ Comment

Eiken Chemical President & CEO Tsugunori Notomi

"We see the NANOTIS method as a groundbreaking technology with the potential to redefine POC Testing, offering instant results far beyond the capabilities of conventional methods. We are excited to collaborate with Nanotis to bring this innovation to life."

Nanotis Corporation CEO, Founder Lisa Sakashita

"It is truly an honor to receive such high recognition from Eiken Chemical, a leader in clinical diagnostics. With the synergy between the two companies, I am confident we will be able to accelerate both our research and business development."

※[1]Nanotis Corporation's core technology NANOTIS Method



※The product concept illustrations in this document are based on the current product vision and are subject to change based on future developments. The actual specifications may differ from what is depicted in this document.

Contact Information

Eiken Chemical
Sustainability Department
TEL: 03(5846)3379
E-mail: koho@eiken.co.jp
Website: https://www.eiken.co.jp

Nanotis Corporation
Public Relations
E-mail: info@nanotis.net